NCT05863858

Eradication of H. Pylori Infection With Moxifloxacin

High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 162 (actual)
• Sponsor: Iyad Naeem Muhammad, PhD · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate, safety, and patient compliance.

Detailed description

Patients who were confirmed to be positive for Helicobacter Pylori infection were randomly assigned to the eradication treatments. At four weeks after completion of eradication therapy, H. pylori tests were performed with a Stool antigen test.

Conditions

• Helicobacter Pylori Infection
• Helicobacter Pylori Infection, Susceptibility to

Interventions

Type	Name	Description
DRUG	Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID	The eradication rate of H. Pylori with levofloxacin-based sequential therapy
DRUG	Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID	The eradication rate of H. Pylori with moxifloxacin-based triple therapy

Timeline

• Start date: 2020-06-01
• Primary completion: 2021-12-01
• Completion: 2022-06-08
• First posted: 2023-05-18
• Last updated: 2023-05-18

Locations

1 site across 1 country: Pakistan